Wall Street brokerages expect TESARO Inc (NASDAQ:TSRO) to post earnings of ($2.66) per share for the current fiscal quarter, Zacks reports. Nine analysts have issued estimates for TESARO’s earnings, with the highest EPS estimate coming in at ($2.44) and the lowest estimate coming in at ($2.89). TESARO posted earnings per share of ($2.82) in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.7%. The company is expected to report its next earnings results on Tuesday, August 14th.

On average, analysts expect that TESARO will report full-year earnings of ($10.08) per share for the current fiscal year, with EPS estimates ranging from ($10.73) to ($9.34). For the next year, analysts forecast that the business will post earnings of ($7.47) per share, with EPS estimates ranging from ($9.14) to ($5.28). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow TESARO.

TESARO (NASDAQ:TSRO) last posted its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($2.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.56) by ($0.42). TESARO had a negative return on equity of 177.92% and a negative net margin of 193.42%. The firm had revenue of $49.74 million for the quarter, compared to the consensus estimate of $56.34 million. During the same period in the prior year, the business earned ($2.55) EPS. TESARO’s quarterly revenue was up 1520.2% compared to the same quarter last year.

TSRO has been the topic of several recent analyst reports. Cann reissued a “buy” rating and set a $122.00 target price (down previously from $199.00) on shares of TESARO in a research report on Tuesday, February 27th. Barclays dropped their target price on shares of TESARO from $135.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 28th. Royal Bank of Canada dropped their target price on shares of TESARO to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 28th. Leerink Swann reissued an “outperform” rating and set a $105.00 target price (down previously from $123.00) on shares of TESARO in a research report on Wednesday, February 28th. Finally, Wells Fargo & Co reissued an “outperform” rating and set a $122.00 target price (down previously from $224.00) on shares of TESARO in a research report on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $112.57.

In related news, Director Lawrence M. Alleva sold 7,142 shares of TESARO stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $43.11, for a total value of $307,891.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 33.70% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in TSRO. TimesSquare Capital Management LLC grew its stake in TESARO by 226.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 856,600 shares of the biopharmaceutical company’s stock valued at $70,986,000 after buying an additional 593,924 shares in the last quarter. BB Biotech AG grew its stake in TESARO by 55.8% in the 1st quarter. BB Biotech AG now owns 1,629,743 shares of the biopharmaceutical company’s stock valued at $93,124,000 after buying an additional 583,550 shares in the last quarter. Renaissance Technologies LLC grew its stake in TESARO by 482.1% in the 4th quarter. Renaissance Technologies LLC now owns 357,400 shares of the biopharmaceutical company’s stock valued at $29,618,000 after buying an additional 296,000 shares in the last quarter. Frontier Capital Management Co. LLC purchased a new position in TESARO in the 1st quarter valued at approximately $13,843,000. Finally, BlackRock Inc. grew its stake in TESARO by 5.6% in the 4th quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock valued at $337,039,000 after buying an additional 213,920 shares in the last quarter.

TESARO stock opened at $49.62 on Thursday. TESARO has a 52 week low of $38.40 and a 52 week high of $153.25. The company has a current ratio of 4.02, a quick ratio of 3.56 and a debt-to-equity ratio of 3.74.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.